Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics

Closed Solicitation Posted

Solicitation number
CBD254-010
Agency
Responses due
Set-aside
Total Small Business

Opportunity facts

More information

Notice details come from DoD SBIR/STTR (DSIP). Updated .

About this opportunity

The Department of the Army Acquisition Support Center, Joint PEO Chemical and Biological Defense, seeks Phase I SBIR proposals for shelf-stable nucleic acid synthesis reagents for field-deployable diagnostics under topic CBD254-010. Proposals were due May 13, 2026, a date that has passed as of November 17, 2026. The set-aside is Total Small Business, and submissions go through the Defense SBIR/STTR Innovation Portal at https://www.dodsbirsttr.mil.

The reagents must remain effective at room temperature, perform reliably from -20C to 55C, maintain a shelf life of at least 12 months, and perform at a level equal to or exceeding existing reagents, which require 4C cold-chain storage. The stated objective is rapid diagnostic test development at the point of need within 30 days in far-forward, expeditionary environments. Improved nucleic acid yield is a secondary government interest. Phase I requires prototype reagents comparable to standard reagents, measured by HPLC and mass spectrometry. Research involving human subjects, animal use, or recombinant DNA cannot be proposed for Phase I. The topic is marked ITAR: No.

The proposal package has five mandatory volumes: coversheet, technical volume (20 pages maximum for Phase I), cost volume, company commercialization report, and supporting documents. Offerors must also complete Fraud/Waste/Abuse training and submit a foreign affiliations disclosure, identifying foreign nationals, green card holders, and dual citizens involved on the project regardless of export control status. The companion release instructions state that Phase I awards are limited to $209,575.00 for up to six months. Selection or non-selection notification follows within 90 days, and Phase I awardees become eligible for Phase II competitions, which are invited no sooner than five months post-award.

Notice text

DoD SBIR topic CBD254-010

Component: CBD

Command: CBD

Phase: SBIR Program Phase I Action

Technology Areas: Bio Medical; Chem Bio Defense

Focus Areas: Biotechnology

Keywords: Expeditionary; Far-Forward; Diagnostics; Rapid Assay Development; Point-of-Need; Nucleic Acid Synthesizer; Manufacturing; Stability; Molecular Assay; Laboratory-Developed Test

ITAR: No

Objective:

Develop novel, shelf-stable reagents for nucleic acid synthesizers that enable the creation of high-quality oligonucleotides for rapid diagnostic test (RDT) development at the point of need in 30 days in a far-forward, expeditionary environment

Description:

The Chemical and Biological Defense Program (CBDP) faces a critical challenge: the need for rapid, deployable diagnostic capabilities in far forward or expeditionary environments. Maintaining the health and readiness of the total force hinges on the ability to rapidly develop and deploy diagnostic assays in response to emerging threats and infectious diseases. However, current technologies present significant limitations. Existing nucleic acid synthesizers rely on reagents that demand cold chain storage at 4°C and possess limited shelf lives. These requirements render them impractical for use in resource-constrained or remote locations, hindering the rapid development and deployment of laboratory-developed tests (LDTs) precisely where they are most needed – at the point of need. To overcome these obstacles, there is an urgent requirement for nucleic acid synthesis reagents exhibiting exceptional stability. These reagents must remain effective at room temperature, perform reliably across a broad range of military operationally relevant conditions, from -20°C to 55°C, and maintain an extended shelf life of at least 12 months, all while performing at a level equal to or exceeding existing reagents. Beyond stability and shelf life, the CBDP is interested in developing reagents that significantly improve the yield of synthesized nucleic acids. This enhanced yield would enable the production of oligonucleotides with higher concentrations and volumes, ideally suited for generating multiple high-quality nucleic acid based molecular assay reagents per synthesis run.

Phase I:

The objective of Phase I is to demonstrate the feasibility of producing nucleic acid synthesis reagents with enhanced stability and shelf life. This will involve developing and testing prototype reagents that meet or exceed the performance of current standard reagents of nucleic acid synthesizers. The prototype reagents should demonstrate stability at room temperature (20-25°C) for an extended amount of time prior to use, function in the device outside of the normal operating temperature range and maintaining equivalent performance to standard reagents. Success will be measured by comparing the performance of the novel reagents with standard reagents in synthesizing a control oligonucleotide sequence, assessing yield and purity using standard analytical techniques (e.g., High-Performance Liquid Chromatography (HPLC), mass spectrometry).

Phase II:

Phase II will focus on optimizing the formulation and manufacturing process for the shelf-stable reagents, scaling up production, and conducting comprehensive stability testing. The deliverable will be a pre-production prototype kit of reagents suitable for use in a commercially available nucleic acid synthesizer. The reagents should demonstrate stability at room temperature (20-25°C) for at least 12 months, function in the device outside of the normal operating temperature range and maintain equivalent performance to standard reagents. The prototype kit will be evaluated by a government identified independent laboratory to assess its performance in synthesizing a panel of relevant oligonucleotide sequences for nucleic acid based molecular assay reagents.

Phase III:

PHASE III: Phase III will focus on transitioning the technology to commercial production and distribution. This will involve securing partnerships with reagent manufacturers and diagnostic companies, obtaining regulatory approvals (if necessary), and developing a comprehensive marketing and sales strategy. Further optimization of the reagent formulation and packaging may be required to meet specific customer needs and market demands. The ultimate goal is to develop reagents that perform reliably across a broad range of military operationally relevant conditions, from -20°C to 55°C, and maintain an extended shelf life of at least 12 months, all while performing at a level equal to or exceeding existing reagents, enabling the rapid development and deployment of diagnostic assays in far-forward and expeditionary environments.

PHASE III DUAL USE APPLICATIONS: Beyond DoD applications, these reagents can be used by commercial diagnostic companies, academic research labs, and public health organizations for rapid assay development and deployment in resource-limited settings.

Files

File Type Posted
CBD254-010.pdf PDF
CBD_SBIR_25.4_R12.pdf PDF

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors